<?xml version='1.0' encoding='utf-8'?>
<document id="28204953"><sentence text="Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation."><entity charOffset="40-60" id="DDI-PubMed.28204953.s1.e0" text="levothyroxine sodium" /><entity charOffset="65-83" id="DDI-PubMed.28204953.s1.e1" text="alendronate sodium" /><pair ddi="false" e1="DDI-PubMed.28204953.s1.e0" e2="DDI-PubMed.28204953.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s1.e0" e2="DDI-PubMed.28204953.s1.e1" /></sentence><sentence text="No clinically important pharmacokinetic interference of alendronate occurred between a new effervescent formulation of alendronate and levothyroxine when coadministered"><entity charOffset="56-67" id="DDI-PubMed.28204953.s2.e0" text="alendronate" /><entity charOffset="119-130" id="DDI-PubMed.28204953.s2.e1" text="alendronate" /><entity charOffset="135-148" id="DDI-PubMed.28204953.s2.e2" text="levothyroxine" /><pair ddi="false" e1="DDI-PubMed.28204953.s2.e0" e2="DDI-PubMed.28204953.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s2.e0" e2="DDI-PubMed.28204953.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s2.e0" e2="DDI-PubMed.28204953.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s2.e1" e2="DDI-PubMed.28204953.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s2.e1" e2="DDI-PubMed.28204953.s2.e2" /></sentence><sentence text=" The combination does not materially affect levothyroxine absorption"><entity charOffset="44-57" id="DDI-PubMed.28204953.s3.e0" text="levothyroxine" /></sentence><sentence text="" /><sentence text="Concurrent treatment of osteoporosis with alendronate (Aln) and hypothyroidism with levothyroxine (LT4) may be problematic because both drugs are to be taken separately after fasting overnight"><entity charOffset="42-53" id="DDI-PubMed.28204953.s5.e0" text="alendronate" /><entity charOffset="55-58" id="DDI-PubMed.28204953.s5.e1" text="Aln" /><entity charOffset="84-97" id="DDI-PubMed.28204953.s5.e2" text="levothyroxine" /><entity charOffset="99-102" id="DDI-PubMed.28204953.s5.e3" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e0" e2="DDI-PubMed.28204953.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e0" e2="DDI-PubMed.28204953.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e0" e2="DDI-PubMed.28204953.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e0" e2="DDI-PubMed.28204953.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e1" e2="DDI-PubMed.28204953.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e1" e2="DDI-PubMed.28204953.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e1" e2="DDI-PubMed.28204953.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e2" e2="DDI-PubMed.28204953.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s5.e2" e2="DDI-PubMed.28204953.s5.e3" /></sentence><sentence text=" The primary objective was to assess pharmacokinetic interactions between a new effervescent formulation of Aln (Aln-NEF) and LT4"><entity charOffset="108-110" id="DDI-PubMed.28204953.s6.e0" text="Aln" /><entity charOffset="113-115" id="DDI-PubMed.28204953.s6.e1" text="Aln" /><entity charOffset="126-128" id="DDI-PubMed.28204953.s6.e2" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s6.e0" e2="DDI-PubMed.28204953.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s6.e0" e2="DDI-PubMed.28204953.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s6.e0" e2="DDI-PubMed.28204953.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s6.e1" e2="DDI-PubMed.28204953.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s6.e1" e2="DDI-PubMed.28204953.s6.e2" /></sentence><sentence text="" /><sentence text="A randomized, open-label, 3-way crossover study was conducted in 30 healthy adults (15 women)" /><sentence text=" Subjects were dosed 3 times, separated by 35 days, after overnight fasts, with Aln-NEF alone (70 mg), LT4 alone (600 μg), or Aln-NEF and LT4 concurrently"><entity charOffset="126-133" id="DDI-PubMed.28204953.s9.e0" text="Aln-NEF" /><entity charOffset="80-86" id="DDI-PubMed.28204953.s9.e1" text="Aln" /><entity charOffset="103-109" id="DDI-PubMed.28204953.s9.e2" text="LT4" /><entity charOffset="138-144" id="DDI-PubMed.28204953.s9.e3" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e1" e2="DDI-PubMed.28204953.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e1" e2="DDI-PubMed.28204953.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e1" e2="DDI-PubMed.28204953.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e1" e2="DDI-PubMed.28204953.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e2" e2="DDI-PubMed.28204953.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e2" e2="DDI-PubMed.28204953.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e2" e2="DDI-PubMed.28204953.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e0" e2="DDI-PubMed.28204953.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s9.e0" e2="DDI-PubMed.28204953.s9.e3" /></sentence><sentence text=" Samples were analyzed for plasma Aln and serum LT4"><entity charOffset="34-36" id="DDI-PubMed.28204953.s10.e0" text="Aln" /><entity charOffset="48-50" id="DDI-PubMed.28204953.s10.e1" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s10.e0" e2="DDI-PubMed.28204953.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s10.e0" e2="DDI-PubMed.28204953.s10.e1" /></sentence><sentence text=" Pharmacokinetic drug-drug interaction was assessed using 90% confidence intervals (CIs) for the test/reference ratio of the geometric means for area under the concentration-time curve from time zero to last measureable time point (AUC0-t ) and maximum concentration (C max)" /><sentence text=" Results were compared to the default no-effect boundaries of 80 to 125% for the ratio Aln-NEF and LT4 concurrently/Aln-NEF alone and the ratio Aln-NEF and LT4 concurrently/LT4 alone"><entity charOffset="87-89" id="DDI-PubMed.28204953.s12.e0" text="Aln" /><entity charOffset="116-118" id="DDI-PubMed.28204953.s12.e1" text="Aln" /><entity charOffset="144-146" id="DDI-PubMed.28204953.s12.e2" text="Aln" /><entity charOffset="99-101" id="DDI-PubMed.28204953.s12.e3" text="LT4" /><entity charOffset="156-158" id="DDI-PubMed.28204953.s12.e4" text="LT4" /><entity charOffset="173-175" id="DDI-PubMed.28204953.s12.e5" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e0" e2="DDI-PubMed.28204953.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e0" e2="DDI-PubMed.28204953.s12.e3" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e0" e2="DDI-PubMed.28204953.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e0" e2="DDI-PubMed.28204953.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e0" e2="DDI-PubMed.28204953.s12.e4" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e0" e2="DDI-PubMed.28204953.s12.e5" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e3" e2="DDI-PubMed.28204953.s12.e3" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e3" e2="DDI-PubMed.28204953.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e3" e2="DDI-PubMed.28204953.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e3" e2="DDI-PubMed.28204953.s12.e4" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e3" e2="DDI-PubMed.28204953.s12.e5" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e1" e2="DDI-PubMed.28204953.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e1" e2="DDI-PubMed.28204953.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e1" e2="DDI-PubMed.28204953.s12.e4" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e1" e2="DDI-PubMed.28204953.s12.e5" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e2" e2="DDI-PubMed.28204953.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e2" e2="DDI-PubMed.28204953.s12.e4" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e2" e2="DDI-PubMed.28204953.s12.e5" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e4" e2="DDI-PubMed.28204953.s12.e4" /><pair ddi="false" e1="DDI-PubMed.28204953.s12.e4" e2="DDI-PubMed.28204953.s12.e5" /></sentence><sentence text="" /><sentence text="Geometric mean ratios (Aln-NEF with LT4/Aln-NEF alone) were 0"><entity charOffset="23-25" id="DDI-PubMed.28204953.s14.e0" text="Aln" /><entity charOffset="40-42" id="DDI-PubMed.28204953.s14.e1" text="Aln" /><entity charOffset="36-38" id="DDI-PubMed.28204953.s14.e2" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s14.e0" e2="DDI-PubMed.28204953.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s14.e0" e2="DDI-PubMed.28204953.s14.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s14.e0" e2="DDI-PubMed.28204953.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s14.e2" e2="DDI-PubMed.28204953.s14.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s14.e2" e2="DDI-PubMed.28204953.s14.e1" /></sentence><sentence text="927 (90% CI 0" /><sentence text="795-1" /><sentence text="081) for AUC0-8 and 0" /><sentence text="912 (90% CI 0" /><sentence text="773-1" /><sentence text="077) for C max, demonstrating LT4 does not appreciably affect the pharmacokinetics of Aln"><entity charOffset="86-88" id="DDI-PubMed.28204953.s20.e0" text="Aln" /><entity charOffset="30-32" id="DDI-PubMed.28204953.s20.e1" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s20.e1" e2="DDI-PubMed.28204953.s20.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s20.e1" e2="DDI-PubMed.28204953.s20.e0" /></sentence><sentence text=" Geometric mean ratios (LT4 with Aln-NEF/LT4 alone) were 1"><entity charOffset="33-35" id="DDI-PubMed.28204953.s21.e0" text="Aln" /><entity charOffset="24-26" id="DDI-PubMed.28204953.s21.e1" text="LT4" /><entity charOffset="41-43" id="DDI-PubMed.28204953.s21.e2" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s21.e1" e2="DDI-PubMed.28204953.s21.e1" /><pair ddi="false" e1="DDI-PubMed.28204953.s21.e1" e2="DDI-PubMed.28204953.s21.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s21.e1" e2="DDI-PubMed.28204953.s21.e2" /><pair ddi="false" e1="DDI-PubMed.28204953.s21.e0" e2="DDI-PubMed.28204953.s21.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s21.e0" e2="DDI-PubMed.28204953.s21.e2" /></sentence><sentence text="049 (90% CI 0" /><sentence text="983-1" /><sentence text="119) for AUC0-48 and 1" /><sentence text="075 (90% CI 1" /><sentence text="006-1" /><sentence text="148) for C max, demonstrating LT4 is bioequivalent between the 2 treatments"><entity charOffset="30-32" id="DDI-PubMed.28204953.s27.e0" text="LT4" /></sentence><sentence text=" Coadministration of Aln-NEF and LT4 was well tolerated"><entity charOffset="21-28" id="DDI-PubMed.28204953.s28.e0" text="Aln-NEF" /><entity charOffset="33-39" id="DDI-PubMed.28204953.s28.e1" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s28.e0" e2="DDI-PubMed.28204953.s28.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s28.e0" e2="DDI-PubMed.28204953.s28.e1" /></sentence><sentence text="" /><sentence text="There was no clinically important pharmacokinetic interference between the Aln-NEF formulation and LT4"><entity charOffset="75-77" id="DDI-PubMed.28204953.s30.e0" text="Aln" /><entity charOffset="99-101" id="DDI-PubMed.28204953.s30.e1" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s30.e0" e2="DDI-PubMed.28204953.s30.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s30.e0" e2="DDI-PubMed.28204953.s30.e1" /></sentence><sentence text=" Aln-NEF does not materially affect LT4 absorption"><entity charOffset="1-3" id="DDI-PubMed.28204953.s31.e0" text="Aln" /><entity charOffset="36-38" id="DDI-PubMed.28204953.s31.e1" text="LT4" /><pair ddi="false" e1="DDI-PubMed.28204953.s31.e0" e2="DDI-PubMed.28204953.s31.e0" /><pair ddi="false" e1="DDI-PubMed.28204953.s31.e0" e2="DDI-PubMed.28204953.s31.e1" /></sentence><sentence text="" /></document>